Azathioprine: TPMT Testing and Dermatologic Indications

Overview / DefinitionAzathioprine is a purine analog that serves as an immunosuppressive agent. It is primarily indicated for the treatment of various dermatologic conditions, particularly those with an autoimmune or inflammatory etiology, such as pemphigus vulgaris, atopic dermatitis, and lupus erythematosus. EpidemiologyAzathioprine is widely used in dermatology and is particularly valuable in managing chronic skin conditions. Its efficacy has been established through clinical trials and extensive real-world experience. The prevalence of conditions treated with azathioprine varies, with pemphigus vulgaris affecting approximately 0.1 to 0.5 per 100,000 individuals, while lupus erythematosus affects around 20 to 150 per 100,000 individuals, depending on geographic and ethnic factors. Pathophysiology / MechanismThe immunosuppressive effects of azathioprine are mediated through its active metabolite, 6-mercaptopurine, which interferes with DNA synthesis and proliferation of lymphocytes. This mechanism is critical in conditions characterized by an overactive immune response. Azathioprine also affects the TPMT enzyme, which plays a significant role in the metabolism of thiopurine drugs. Clinical PresentationPatients receiving azathioprine may present with various dermatologic conditions, including: Pemphigus vulgaris Atopic dermatitis Lupus erythematosus Chronic graft-versus-host disease Other autoimmune skin disorders Clinical response to azathioprine can take several weeks to months, and regular monitoring for signs of efficacy and toxicity is essential. Diagnosis / WorkupThe diagnosis of conditions treated with azathioprine typically involves a combination of clinical evaluation, laboratory tests, and histopathological examination. Before initiating treatment, it is crucial to perform TPMT testing to assess the patient's enzyme activity: Normal TPMT activity: standard dosing of azathioprine Intermediate TPMT activity: consider dose reduction Low or absent TPMT activi